Compare Oxford Lane Capital Corp (OXLC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs TG Therapeutics Inc — how do they compare? Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 9.8× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 50 Days and TG Therapeutics Inc for 16 Days on average.
| OXLC | TGTX | |
|---|---|---|
Market Cap | $835.71M | $8.16B |
Volume | 1,125,263 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $16.74 | $59.06 |
52-Week Low | $8.15 | $26.94 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | $1.23B | $8.37B |
Dividend Yield | 28.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.56, up 1.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows a low P/B of 0.81 and pays a consistent $0.20 monthly dividend. However, recent earnings have significantly missed expectations, with a Q1 2026 loss of -$6.23 per share, and 2026 revenue and net profit trends are deeply negative, raising sustainability concerns.
The outlook is highly speculative. The deep discount to book value and high dividend yield present a potential value opportunity for income-focused investors, but this is offset by severe profitability erosion, negative cash flow from operations, and analyst skepticism. Key risks include the company's ability to stabilize its net asset value and fund its dividend without further capital erosion.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
